[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507446":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":40,"centralContacts":44,"locations":49,"responsibleParty":216,"collaborators":33,"id":218,"slug":33,"hasResults":219,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":33,"eligibilityCriteria":223,"healthyVolunteers":219,"sex":224,"minAge":225,"maxAge":33,"enrollmentInfo":226,"targetDuration":33,"studyType":229,"phases":230,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":52,"whyStopped":33,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},{"fullName":5,"class":6},"Tango Therapeutics, Inc.","INDUSTRY",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD",[13,14],"Drug: TNG260","Drug: Pembrolizumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion in NSCLC with KRAS Mutation","Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Dose Expansion in NSCLC with KRAS Wild type","Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Dose Expansion in Advanced or Metastatic Solid Tumors","Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab",[13,14],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","TNG260","CoREST inhibitor, administered orally",[9,24,16,20],null,{"type":29,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Pembrolizumab","Pembrolizumab, an anti-PD-1 antibody, administered intravenously",[9,24,16,20],[39],"Keytruda",[41],{"name":42,"affiliation":5,"role":43},"Adam Crystal, MD, PhD","STUDY_DIRECTOR",[45],{"name":42,"role":46,"phone":47,"phoneExt":33,"email":48},"CONTACT","8573204899","clinicaltrials@tangotx.com",[50,67,80,93,106,119,131,144,154,167,180,192,205],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"UCLA Hematology\u002FOncology","RECRUITING","Santa Monica","California","90404","United States",{"type":58,"coordinates":59},"Point",[60,61],-118.49138,34.01949,{"lat":61,"lon":60},[64],{"name":65,"role":66,"phone":33,"phoneExt":33,"email":33},"Jonathan Goldman, MD","PRINCIPAL_INVESTIGATOR",{"facility":68,"status":52,"city":69,"state":70,"zip":71,"country":56,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"SCRI at HealthOne","Denver","Colorado","80218",{"type":58,"coordinates":73},[74,75],-104.9847,39.73915,{"lat":75,"lon":74},[78],{"name":79,"role":66,"phone":33,"phoneExt":33,"email":33},"Gerald Falchook, MD",{"facility":81,"status":52,"city":82,"state":83,"zip":84,"country":56,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Florida Cancer Specialists","Sarasota","Florida","34232",{"type":58,"coordinates":86},[87,88],-82.53065,27.33643,{"lat":88,"lon":87},[91],{"name":92,"role":66,"phone":33,"phoneExt":33,"email":33},"Judy Wang, MD",{"facility":94,"status":52,"city":95,"state":96,"zip":97,"country":56,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":58,"coordinates":99},[100,101],-71.05977,42.35843,{"lat":101,"lon":100},[104],{"name":105,"role":66,"phone":33,"phoneExt":33,"email":33},"Mark Awad, MD, PhD",{"facility":107,"status":52,"city":108,"state":109,"zip":110,"country":56,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Henry Ford Health System","Detroit","Michigan","48202",{"type":58,"coordinates":112},[113,114],-83.04575,42.33143,{"lat":114,"lon":113},[117],{"name":118,"role":66,"phone":33,"phoneExt":33,"email":33},"Shiresh Gadgeel, MD",{"facility":120,"status":52,"city":121,"state":109,"zip":122,"country":56,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"START MidWest","Grand Rapids","49546",{"type":58,"coordinates":124},[125,126],-85.66809,42.96336,{"lat":126,"lon":125},[129],{"name":130,"role":66,"phone":33,"phoneExt":33,"email":33},"Manish Sharma, MD",{"facility":132,"status":52,"city":133,"state":134,"zip":135,"country":56,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"NYU Langone Hematology Oncology Associates-Mineola","Mineola","New York","11501",{"type":58,"coordinates":137},[138,139],-73.64068,40.74927,{"lat":139,"lon":138},[142],{"name":143,"role":66,"phone":33,"phoneExt":33,"email":33},"Salman Punekar, MD",{"facility":145,"status":52,"city":134,"state":134,"zip":146,"country":56,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"New York University Langone Health","10016",{"type":58,"coordinates":148},[149,150],-74.00597,40.71427,{"lat":150,"lon":149},[153],{"name":143,"role":66,"phone":33,"phoneExt":33,"email":33},{"facility":155,"status":52,"city":156,"state":157,"zip":158,"country":56,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Sarah Cannon Tennessee Oncology","Nashville","Tennessee","37203",{"type":58,"coordinates":160},[161,162],-86.78444,36.16589,{"lat":162,"lon":161},[165],{"name":166,"role":66,"phone":33,"phoneExt":33,"email":33},"David Spigel, MD",{"facility":168,"status":52,"city":169,"state":170,"zip":171,"country":56,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"US Oncology Investigational Products Center","Dallas","Texas","75246",{"type":58,"coordinates":173},[174,175],-96.80667,32.78306,{"lat":175,"lon":174},[178],{"name":179,"role":66,"phone":33,"phoneExt":33,"email":33},"Kartik Konduri, MD",{"facility":181,"status":52,"city":182,"state":170,"zip":183,"country":56,"cosmosGeoPoint":184,"geoPoint":188,"contacts":189},"The University of Texas MD Anderson Cancer Center","Houston","77030",{"type":58,"coordinates":185},[186,187],-95.36327,29.76328,{"lat":187,"lon":186},[190],{"name":191,"role":66,"phone":33,"phoneExt":33,"email":33},"Ferdinandos Skoulidis, MD",{"facility":193,"status":52,"city":194,"state":195,"zip":196,"country":56,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"NEXT Oncology Virginia","Fairfax","Virginia","22031",{"type":58,"coordinates":198},[199,200],-77.30637,38.84622,{"lat":200,"lon":199},[203],{"name":204,"role":66,"phone":33,"phoneExt":33,"email":33},"Alex Spira, MD",{"facility":168,"status":52,"city":206,"state":195,"zip":207,"country":56,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Norfolk","23502",{"type":58,"coordinates":209},[210,211],-76.28522,36.84681,{"lat":211,"lon":210},[214],{"name":215,"role":66,"phone":33,"phoneExt":33,"email":33},"Jedrzej Wykretowicz, MD",{"type":217,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100507446",false,"NCT05887492","Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","A Phase 1\u002F2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors","Inclusion Criteria:\n\n* Is ≥18 years of age at the time of signature of the main study ICF.\n* Has ECOG performance status of 0 or 1.\n* Has measurable disease based on RECIST v1.1.\n* All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method\n* Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor.\n* Adequate organ function\u002Freserve per local labs\n* Adequate liver function per local labs\n* Adequate renal function per local labs\n* Negative serum pregnancy test result at screening\n* Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n* Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients\n* Uncontrolled intercurrent illness that will limit compliance with the study requirements\n* Active infection requiring systemic therapy\n* Currently participating in or has planned participation in a study of another investigational agent or device\n* Impairment of GI function or disease that may significantly alter the absorption of oral TNG260\n* Active prior or concurrent malignancy.\n* Central nervous system metastases associated with progressive neurological symptoms\n* Current active liver disease from any cause\n* Clinically relevant cardiovascular disease\n* A female patient who is pregnant or lactating","ALL","18 Years",{"count":227,"type":228},126,"ESTIMATED","INTERVENTIONAL",[231,232],"PHASE1","PHASE2","The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.\n\nThe main question\\[s\\] it aims to answer are:\n\n* the recommended dose for Phase 2\n* to evaluate the safety and tolerability of the combination therapy\n* to determine the pharmacokinetics of TNG260\n* to evaluate the initial antineoplastic activity\n\nParticipants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.",[235,236,237,238],"Non Small Cell Lung Cancer","Solid Tumors, Adult","Lung Cancer","Lung Adenocarcinoma",[240,241,242],"STK11","KRAS wild type","LKB1","2025-11-14",{"date":245,"type":246},"2025-11-18","ACTUAL",{"date":248,"type":246},"2023-06-12",{"date":250,"type":228},"2026-06",{"name":5,"class":6},13]